Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients < 4 Months of Age
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacokinetics
- Sponsors Roche
- 30 Aug 2016 Results published in the Pediatric Infectious Disease Journal
- 13 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Jul 2013 Planned end date changed from 1 Apr 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.